Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial Feb 9, 2021
Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021 Jan 20, 2021